RE:RE:RE:More OptionsI'm fine with the options granted as the company has grown quite a bit in the last year. No debt, 20 million in the bank and AI growing substantially.
However, I will also agree the with those that the share price certainly doesn't show that growth and that is an issue. Unfortunately, it's an issue that is not entirely in their hands. Hopefully with the PR and more institutional meetings, as mentioned by Marshall, that will change very quickly. And from the wall of shares today, it looks to be the case.
We have Q4 financials, Year end financials and Q1 financials all in the next four months. We all know the first two will certainly blow last years financials out of the water and Q1 2022 will probably be similar or higher than the $19 million from Q1 2021.
Given the 300% increase in testing who knows what Q1 will actually be as we don't have numbers of on how many are PCR and how many are antigen tests or the number of people being tested. I know another poster mentioned that her husband works in the movie industry in Toronto and I believe she commented that they were doing PCR testing. That would make sense as the movie industry would want the most accurate form of tests and when the testing contract was signed last year they were doing PCR tests. I would assume that has not changed. If that is the case, than a 300% increase in testing could mean close to $60 million in one quarter based on a similar number of people being tested last year in Q1. Mind blowing numbers for a small cap. I don't think that will be the case, but I'll be interested to see.